I don’t know if this us fake news
LOW doses of steroids widely prescribed to treat a range of inflammatory diseases may be linked to an increased risk of cardiovascular diseases, research has found.
For patients using less than five milligrams of prednisolone (a standard glucocorticoid) per day, the risk of cardiovascular disease nearly doubled, compared with patients not using glucocorticoids.
While high doses of steroids are known to increase the risk of cardiovascular disease, scientists say the impact of lower doses was previously unknown.
Prednisolone is used to treat a wide range of health problems including allergies, blood disorders, skin diseases, infections, certain cancers and to prevent organ rejection after a transplant.
Figures from 2011 show that about 1 per cent of the general population receives systemic glucocorticoids. Long-term oral glucocorticoid prescriptions had increased by 34 per cent over the 20 years before then.
In a study published yesterday, researchers analysed medical records of 87,794 patients diagnosed with six different immune-mediated inflammatory diseases in the UK from 1998-2017.
They found that even patients taking low doses may have double the risk of developing cardiovascular diseases.
Increased dose-dependent risks were found across all measured cardiovascular diseases, including atrial fibrillation, heart failure, acute myocardial infarction, peripheral arterial disease, cerebrovascular disease, and abdominal aortic aneurysm.
The researchers say it was previously thought that taking 5mg of glucocorticoid over the long term was safe.
According to the researchers, the study indicates patients needing long-term steroid treatment should be prescribed the lowest effective dose.
The study published in PLOS Medicine by Mar Pujades-Rodriguez at Leeds University, suggests patients should have a personalised cardiovascular risk prevention plan that accounts for past and current steroid use. The researchers write: “These results highlight the importance of prompt and regular monitoring of cardiovascular risk and use of primary prevention treatment at all glucocorticoid doses.”
However, Kevin McConway, emeritus professor of applied statistics at The Open University, said: “It’s important to note that these results don’t tell us anything direct about people who take this type of steroid drug for other health conditions, because such people were not included in this study.
“They also don’t tell us about steroid drugs being taken by other routes (such as inhalers) rather than swallowing them.
“It’s also important to note that, even of the patients with the particular inflammatory diseases that they studied, the researchers found that a great number of them were not using the drugs in question. Only 16 per cent of them had been prescribed oral glucocorticoids in the year before the researchers started following them up.”
He added: “Some of the increases in risk, even for people taking relatively small doses of these drugs compared to people taking none at all, may sound somewhat alarming, but this has to be put into the context that the risks are not huge to begin with.
“The researchers estimated that the risk of cardiovascular disease, in people with the diseases in question who did not use these drugs at all, was 1.4 per cent in a year, which is not particularly large given their average age (they were 58, on average, when they entered the study).”